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Abstract
Background: There is a growing interest in developing tailored non-pharmacological strategies to face patients’
needs in dementia. Occupational therapy (OT) may contribute to promote self-empowerment of both patients and
caregivers. France has implemented nationwide OT over a short-term period of 3/4 months. The main objective of
the MathéoAlz study is to measure the impact of maintaining OT over 4 supplementary months on patients’
neuropsychiatric symptoms.
Methods/design: The MatheoAlz trial (Maintenance of Occupational Therapy in Alzheimer’s disease) is a multi-
center, pragmatic randomized controlled trial testing maintenance of OT over 4 supplementary months compared
to routine OT delivered as recommended. This paper describes the study protocol. MatheoAlz plans to enroll 240
dyads, i.e. dementia patients and caregivers, whose main inclusion criteria are: prescription for routine OT, patients
with mild or moderate dementia, living at home, receiving support from an informal caregiver. The study will
compare a control group of patients benefiting from 12 to 15 initial sessions of OT over 3/4 months and an
intervention group of patients benefiting from these initial sessions plus 8 extra home sessions over 4 supplementary
months. The main outcome is the patient’s neuropsychiatric symptoms assessed by the Neuropsychiatric Inventory at
8 months. Several clinical outcomes and economic consequences are measured at 4, 8 and 12months.
Discussion: This is the first trial designed to assess the specific impact of the maintaining OT on the patients’
neuropsychiatric symptoms burden. The results will inform policymakers on strategies to implement in the
near future.
Trial registration: This trial was registered at ClinicalTrials.gov on February 16, 2018, identifier: NCT03435705.
Keywords: Alzheimer’s disease, Dementia, Occupational therapy, Randomized controlled trial, Informal caregiver,
Neuropsychiatric symptoms, Home intervention
Background
About 6 million people are currently affected by dementia
in Europe [1]. The majority of people with dementia live
at home. Living in their own familiar environment may
enable people with dementia to maintain their social net-
works and enjoy a better quality of life [2]. However, they
experience a progressive cognitive and functional decline,
limiting their ability to perform activities and to commu-
nicate; they also have frequent behavioral symptoms that
are challenging for the caregivers and interfere with their
daily functioning [3]. The progressive loss of social inter-
actions contributes to reduce personal engagement in
meaningful daily activities [4, 5]. Yet, engaging persons
with dementia in personally-tailored activities may have
positive effects on their challenging behaviors and quality
of life. These benefits might positively influence caregivers’
burden and well-being. In France, a massive effort was
made to optimize dementia care through a national
Alzheimer plan 2008–2012 [6]. Several innovative health
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care services have been implemented nationwide, notably
home services offering care plan based on occupational
therapy (OT) model. OT allows tailored home support by
cognitive and social rehabilitation for subjects with
mild-to-moderate dementia; it aims to restore or mobilize
the remaining abilities of individuals and adapt their
domestic environment. The French OT model involves
occupational therapists, psychomotor therapists and ge-
rontologic assistants.
A growing interest in OT currently exists and some
trials are ongoing [7, 8]. A review has concluded that lit-
erature provided a “proof of concept” that functional de-
cline related to dementia may be delayed via OT
interventions [9]. A 5-weeks OT’s program demon-
strated clinical efficacy on daily functioning at 12 weeks
in the Netherlands [10–12]. Nevertheless, the interven-
tion’s replication in another national context failed to
demonstrate any effectiveness [13]. Moreover, a recent
US trial failed to demonstrate that OT added to collab-
orative care improves daily functioning over a 2-year
period. It remains unclear whether results observed in
efficacy trials with convenience and homogeneous sam-
ples are similarly obtained in routine care context. Par-
ticipants who are typically volunteers for such trials
differ from non-volunteers providing similar levels of
care [14]. Yet, real-world studies are scarce. Recently,
within an observational study based on routine care
practice we showed that patients benefiting from OT ex-
perienced a stabilization in their functional perfor-
mances over the 3/4 months intervention period before
a worsening phase [15]. They also reported a decrease of
their behavioral troubles followed by a stabilization
phase. The French model of OT is a short-term inter-
vention that enters into the intimacy of the daily func-
tioning of patients and their caregivers, and the end of
the intervention can be disruptive in a context of social
and psychological frail equilibrium. Moreover, planning
and implementation of relays (such as speech therapists,
physiotherapists or personal care assistant) after OT are
crucial to maintain therapeutic approaches according to
patients’ care needs. Nevertheless, these tasks are time
consuming and complex to accomplish in the devoted
period. This report describes a protocol being used in an
ongoing randomized trial aiming to provide evidence on
long-term clinical effectiveness and economic conse-
quences of maintaining OT over 4 extra months.
Methods/design
Aims and study hypothesis
The MatheoAlz trial (Maintenance of Occupational
Therapy in Alzheimer’s disease) is a multi-center, prag-
matic randomized controlled trial testing routine OT de-
livered as recommended compared to maintenance of
OT over four supplementary months. After completion
of the initial clinical assessment, participants are ran-
domly allocated into the control group (treatment as
usual with 12 to 15 home sessions over 3/4 months) or
the treatment group (12 to 15 home sessions over 3/4
months + extra 8 sessions over 4 months). In order not
to influence care practice and care organization in the
control group, we decided to adopt a pragmatic
approach. Thus, ESAs therapists provide routine care as
usual in patients randomized in the control group. In
this way, maintenance of OT will be compared to
real-world care provided by ESAs therapists.
Setting and participants
The study is being conducted in the South West of
France; it began in 2018 and will run until 2019. Recruit-
ment takes place through ESA (French acronym for
“Equipe Spécialisée Alzheimer”) that are specialized
teams of health professionals intervening at home for
dementia patients. Patients are referred to ESA under
medical prescription. We selected 10 ESA that were
already involved in the pilot study (described elsewhere)
and showed a high recruitment capacity [15]. Moreover,
patients cared by these settings have been shown to be
representative of the patients care by ESA at the national
level [16]. All ESA staff met University research team for
research compliance and human subject data collection.
Eligibility criteria were pragmatically chosen to be repre-
sentative of situations encountered by therapists in their
routine care practice. Patients’ inclusion criteria include
having a dementia diagnosis, being referred to an ESA
for the first time, a MMSE score over 15, living in the
community or in residential care setting and having a
non-professional caregiver. Exclusion criteria are listed
as follow: institutionalized patients or patients with a
short-term project of institutionalization, patients with
reported behavior of care refusal, patients already in-
cluded in a non-pharmacological trial, patients under
legal protective measures or not able to provide their
written consent for participation in the study, patients
or caregivers with characteristic that could affect partici-
pation (e.g.: major physical illness; sensory impairment;
disability). People with dementia meeting the inclusion
criteria will be recruited over an inclusion period of 10
months, this timeframe was estimated based on ESA’s
inclusion capacity.
Study procedures and randomization
Randomization will be performed with a 1:1 ratio, and
will be stratified by territory nature (urban vs rural) and
presence of gerontological coordination center in the
area (yes vs no) in order to avoid imbalances on major
characteristics that might influence care strategies and
care effectiveness (see Fig. 1). Randomization process is
centralized via a website accessible for each investigator
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allowing random allocation. Although patients cannot be
blinded to their allocation treatment, all follow-ups as-
sessments are gathered by assessors (psychologists)
blinded to treatment allocation. Even if we cannot ex-
clude that patients or/and caregivers inform inadvert-
ently interviewers of the treatment they are receiving,
we aim to reduce this hazard by giving explicit re-
minders to participants before randomization and by the
use of self-measure whenever it is feasible.
Consent for participating to the study was signed by each
participant after they received a full explanation in person,
with the opportunity to ask questions to therapists. All par-
ticipants have the right to decline participation or with-
draw from the study at any time without giving a reason.
The study protocol, information brochure and informed
consent procedure were approved by the medical ethics
committee for Human (Comité de protection des per-
sonnes d’Ile de France 1, 6th November 2017) and the
study was registered in clinical trial (NCT03435705).
Usual care
The participants allocated to the control group benefit
from the usual intervention described previously [15].
Briefly, patients referred to ESA followed a standardized
treatment procedure consisting of 12 to 15 home ses-
sions performed by a therapist over a period of 3/4
months focusing on patients and potential primary care-
givers. The initial assessment (1 or 2 sessions) allows the
therapist to evaluate remaining abilities, and to define
patients’ and caregivers’ expectations and needs. In the
following sessions, patients were taught to optimize
compensatory and environmental strategies to improve
their performance in daily activities. Through demon-
stration with patients, primary caregivers were trained to
use effective supervision, problem solving, manage situ-
ational distress and coping strategies to sustain patients’
social participation. Caregivers also learned to simplify
activities for future decline and how to use strategies to
other daily care challenges. At the end, few sessions
could be devoted, according to patients and caregivers’
expectations and needs, to initiate and prepare home
care support following the initial OT intervention.
Intervention
As described above, providing meaningful and tailored
activities according to patients and caregivers’
Fig. 1 Flowchart of study design
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expectations and needs is the core of OT. The thera-
peutic approach includes environmental modifications,
behavior management, physical activity, and emotional
support as active components. As for the control group,
the intervention group will have a first period of 3/4
months consisting of 12 to 15 home sessions; after this
period the intervention group will have a maintenance
of OT over 4 supplementary months with 8 extra ses-
sions. This maintenance of OT over a longer period
aims to optimize therapeutic approaches implemented
during the initial 12/15 sessions by 1°) reinforcing care-
givers’ confidence and competency and 2°) allowing a
better matching between individual needs and further
home care support.
Outcome measures
Primary and secondary measures are assessed after the
initial planned intervention (first follow-up, M4), at 8
months (second follow-up M8) and at 12 months (third
follow-up, M12). All outcomes and the timetable are
shown in Table 1.
Primary outcome measure
a) Behavior symptoms are measured with the Neuro-
psychiatric Inventory (NPI), that assesses the frequency
and the severity of the symptoms as well as the caregiver
distress in 12 behavioral domains (delusions, hallucina-
tions, depression/dysphoria, anxiety, agitation/aggres-
sion, elation/euphoria, disinhibition, irritability/lability,
apathy/indifference, aberrant motor activity, sleep/night
time behavior, and appetite/eating). NPI is given as an
interview questionnaire [17]. Each domain is rated by
the caregiver in terms of both frequency (1–4) and se-
verity (1–3), yielding a composite symptom domain
score (frequency×severity). The total composite score is
obtained by summing up the single item scores, which
may range from 0 to 144, with higher scores indicating
more behavioral problems.
Secondary outcomes
b) Quality of life is measured using the Quality of
Life-Alzheimer’s disease Scale (QOL-AD) [18]. The
QOL-AD covers 13 domains of quality of life. It has
good internal consistency, validity and reliability and its
use is recommended by the European consensus on out-
come measures for psychosocial interventions in demen-
tia [19]. The scale presents high psychometrics
properties whatever the dementia etiologies [20].
c) Functional performances are measured with the Dis-
ability Assessment in Dementia (DAD). This scale assesses
10 basic and instrumental activities of daily living and
decomposed each activity into initiation, organization and
efficacy. The sensitivity and reliability have been estab-
lished [21].
d) Apathy is measured using the apathy inventory [22],
that assesses emotional fatigue, initiative loss and inter-
est loss. Psychometric properties are good [23].
e) Depression is assessed using Montgomery-Asberg
Depression Rating Scale (MADRS) [24]. This scale
explores 10 dimensions: apparent sadness, expressed
sadness, inner tension, reduced sleep, reduced appetite,
concentration difficulties, lassitude, inability to feel, pes-
simistic thoughts, suicidal thoughts. The MADRS is one
of the most reliable scale to detect depressive symptoms
in dementia population independently of the stage of se-
verity [25].
f ) Caregivers’ burden is assessed using the Zarit
Burden Index (ZBI) [26]. The ZBI is a subjective meas-
ure of burden that includes 22 items exploring the care-
giver’s perception and feelings about care situations.
g) Caregivers’ sense of competence is assessed with the
sense of competence questionnaire [27].
h) Vital status and institutionalization and their dates
are assessed at each follow-up using any sources of data
available (main caregivers or the general practitioner).
i) Patients’ resource utilization is measured for the
month prior to the visit using the Resource Use in Demen-
tia (RUD) [28]. The RUD questionnaire was specifically de-
signed to estimate formal resource utilization (primary
and secondary care consultation, hospitalizations, social
care services funded or brokered by local authorities…) as
well as informal care for dementia-related activities. Pri-
mary caregivers are asked to notify the number of days
and time spent for formal and informal caregiving activ-
ities provided during the month prior to the visit.
j) Process of care in relation with dementia is assessed
by asking caregivers for current use of anti-dementia drug,
antidepressant drug, antipsychotic drug, consultation with
Table 1 Overview of instruments (measures) in the MatheoAlz
trial
Inclusion M4 M8 M12
MMSE ✓
NPI ✓ ✓ ✓ ✓
DAD ✓ ✓ ✓ ✓
MADRS ✓ ✓ ✓
Apathy inventory ✓ ✓ ✓
Zarit ✓ ✓ ✓
RUD ✓ ✓ ✓
Sense of competence questionnaire ✓ ✓ ✓
Apathy Inventory ✓ ✓ ✓
QOLAD ✓ ✓ ✓
MMSE: Mini Mental State Examination
NPI: NeuroPsychiatric Inventory
DAD: Disability Assessment in Dementia
MADRS: Montgomery-Asberg Depression Rating Scale
QOLAD: Quality of Life in Dementia
RUD: Ressource Utilization in Dementia
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a specialist (memory clinic, neurologist with private activ-
ity, psychiatrist, geriatrician) in the previous 3months,
speech therapist use, presence and type of home help sup-
port, financial subsidies support, and adult day care use.
Economic evaluation
In order to provide useful and complete information for
national decision makers, we propose also an economic
evaluation in this project aiming at assessing:
- the total costs of patient care and disease manage-
ment from a societal perspective spanning public ser-
vices (hospitalization, primary and secondary care),
social care services funded by local authorities as well as
indirect cost associated with informal care. The extra
sessions will be fully costed to generate a program cost
and cost per participant;
- the cost-effectiveness ratio, expressed at the cost per
avoided institutionalization at 12 months. This will be
the first study to provide this kind of ratio.
- the net benefit for the French Healthcare system to
widespread OT during 4 months more.
Sample size
The sample size was based upon: a) the primary outcome
(NPI) at 8 months; b) treatment effect sizes for outcome
from the pilot study and other non-pharmacologic trials;
c) ability to detect a clinical significant reduction of NPI
score of 5 points: expected means (standard errors) were
16 (14) for control group and 11 (11) for intervention
group; and d) a type I error rate of 0.05. An effect smaller
than 5% would bring us at or near levels where the study
could have statistical but not clinical significance as dem-
onstrated by Mega et al. [29]. To attain 80% power for a
two-sided comparison of the two treatment groups with
an estimated attrition of 15%, a sample size of 240 is
required.
Statistical analyses
Analyses will be performed by intention to treat, in that
all available data will be included. Methods of imput-
ation such as last observation carried forward are of lim-
ited utility in dementia, because the expectation is
decline for the usual treatment group, and most attrition
will be due to death or assessment refusal. Therefore, for
primary analysis missing data will be replaced by the
“missing = failure” strategy, with sensitivity analyzes
using maximum bias strategies, missing value modeling
and nonresponse modeling, with a particular attention
on death or institutionalization of patients. Depending
on the outcome distribution, linear or non-linear mixed
models will test the hypotheses, including the time of
measurement (within-subject factor), the experimental
condition (between-subject factor) and the interaction
between these two factors.
Discussion
This is an innovative randomized controlled trial that
evaluates the effectiveness and cost-effectiveness of
maintaining OT for people with dementia and their
caregivers. This health service research is of great im-
portance since development of OT nationwide through
ESA has modified routine dementia care notably for
early stages. ESAs are often the first step when the func-
tional issues arise and constitute a cornerstone in care
practice for both general practitioners and specialists’
physicians. Nevertheless, deviations to recommendations
exist [15] and criticism towards the intervention format
have been raised [30]. Recent study suggested that a tai-
lored activity program delivered by occupation therapists
for veterans with dementia leaded to short-term clinic-
ally relevant benefits but these benefits do not extend
for a longer period after a “wash-out period” without ac-
tive program [31]. Thus, it seems necessary to investi-
gate ways to improve effectiveness of OT.
The French guidelines for dementia care offer very few
evidence-based recommendations on psychosocial
approaches, due to a paucity of high quality RCTs.
Moreover, evidence from trials testing routine care prac-
tice is still too scarce in dementia. Because of the in-
crease of dementia prevalence, optimizing cost-effective
therapeutic approaches that primary target patients and
caregivers needs appears crucial. Important advantages
of the present trial nested in care settings are that the
nationwide implementation could let a high level of
generalizability and the tested strategy is easily replicable
in routine practice.
Primary outcome measure is severity of patient’s be-
havioral symptoms. The latter add considerable burden
to individuals and substantially contribute to health care
utilization, early institutionalization and higher care
costs. There are few effective and safe pharmacological
treatments for behavioral symptoms leading to difficul-
ties for addressing these troubles. As exacerbation of
some symptoms often occur in the context of care
provision, transfer of knowledge and specific techniques
to prevent and/or manage such behaviors may be useful
in daily functioning. Because the purpose of OT is to
promote a sense of self, new ways to accomplish basic
pleasant tasks, maintaining such therapy over a longer
period may bring potential benefits on the different do-
mains we plan to assess such as patient’s quality of life,
apathy, depressive symptoms, functional impairment as
well as caregiver feelings of burden and sense of compe-
tence. These outcomes are recommended for psycho-
social intervention research in dementia care [19].
This study is likely to influence the availability, provi-
sions, uptake and maintenance of OT in France and
internationally, and may also impact on current
evidence-based guidelines and policies relating to
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dementia care. Our findings will have broad clinical sig-
nificance in that if positive, it would provide an
evidence-based approach to help families to manage
challenging behaviors. Null findings would provide a bet-
ter understanding of the effect of OT’ duration on dis-
ease progression.
Implementation of cost-effective therapeutic ap-
proaches targeting early dementia stages are of great im-
portance [32]. This study should provide evidence of the
efficacy of maintenance OT on behavioral symptoms of
persons with dementia and psychological symptoms in
their informal caregivers.
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